Skip to main content
OpenTrials

Clinical trial condition

Blood Protein Disorders

Explore clinical trials studying Blood Protein Disorders. Study availability and eligibility vary by location and protocol.

3,075 public trials 570 recruiting studies
Refine in advanced search Browse all conditions

Blood Protein Disorders trial results

Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Cancer Center-Scottsdale Phoenix, Arizona, United States
  • City of Hope Duarte, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Stanford University Medical Center Stanford, California, United States
View all 50 locations
View Trial Details
Recruiting

A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

NCT07665450

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Rambam Med.Center - Hematology Institute Haifa, Israel
  • Carmel Medical Center Haifa, Israel
  • Shaare Zedek Medical Center Jerusalem, Israel
  • Rabin Medical Center Petah Tikva, Israel
View all 19 locations
View Trial Details
Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • UCSF Fresno Clovis, California, United States
  • City of Hope Duarte Duarte, California, United States
View all 270 locations
View Trial Details
Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Jupiter Medical Center/Anderson Family Cancer Institute Jupiter, Florida, United States
  • MSK Basking Ridge Basking Ridge, New Jersey, United States
  • MSK Monmouth Middletown, New Jersey, United States
  • MSK Bergen Montvale, New Jersey, United States
View all 160 locations
View Trial Details
Recruiting

Study on the Clinical Efficacy of Teclistamab and Talquetamab

NCT06477783

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Imelda Bonheiden, Antwerpen, Belgium
  • Universitair Ziekenhuis Antwerpen (UZA) Edegem, Antwerpen, Belgium
  • Grand Hôpital de Charleroi Charleroi, Henegouwen, Belgium
  • EpiCURA Hornu, Henegouwen, Belgium
View all 17 locations
View Trial Details
Recruiting

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Highlands Oncology Group Springdale, Arkansas, United States
  • Valkyrie Clinical Trials Los Angeles, California, United States
  • Emory University Atlanta, Georgia, United States
  • Nebraska Cancer Specialists Omaha, Nebraska, United States
View all 173 locations
View Trial Details
Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05160584

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • LKH Leoben Leoben, Austria
  • Krankenhaus der barmherzigen Schwestern Vienna, Austria
  • UZ Antwerpen Edegem, Belgium
  • Ziekenhuis Oost-Limburg Genk, Belgium
View all 90 locations
View Trial Details
Recruiting

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

NCT07336472

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Honor Health Scottsdale, Arizona, United States
  • City of Hope - Duarte Duarte, California, United States
  • City of Hope - Lennar Irvine, California, United States
  • Emory Atlanta, Georgia, United States
View Trial Details
Recruiting

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

NCT06948084

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States
  • Illinois CancerCare-Bloomington Bloomington, Illinois, United States
  • Illinois CancerCare-Canton Canton, Illinois, United States
  • Illinois CancerCare-Carthage Carthage, Illinois, United States
View all 14 locations
View Trial Details
Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

NCT04728893

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Lymphocytic Leukaemia, +24 more
Locations
  • Highlands Oncology Group ( Site 2728) Springdale, Arkansas, United States
  • University of California San Diego Moores Cancer Center ( Site 2717) La Jolla, California, United States
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724) Torrance, California, United States
  • Colorado Blood Cancer Institute ( Site 2726) Denver, Colorado, United States
View all 121 locations
View Trial Details

Related conditions